Cardiovascular outcomes trials with incretin-based medications: a critical review of data available on GLP-1 receptor agonists and DPP-4 inhibitors

6533b85ffe1ef96bd12c1206

RESEARCH PRODUCT

Cardiovascular outcomes trials with incretin-based medications: a critical review of data available on GLP-1 receptor agonists and DPP-4 inhibitors

Ali A. Rizvi Omer H Tarar Anca Pantea Stoian Manfredi Rizzo Nikolaos Papanas Dragana Nikolic Alexandros Sachinidis

subject

0301 basic medicine endocrine system medicine.medical_specialty Dipeptidyl Peptidase 4 Endocrinology Diabetes and Metabolism Incretin 030209 endocrinology & metabolism Class effect Body weight Cardiovascular System Incretins Glucagon-Like Peptide-1 Receptor 03 medical and health sciences 0302 clinical medicine Endocrinology Internal medicine Type 2 diabetes mellitus medicine Animals Humans Intensive care medicine Glucagon-like peptide 1 receptor Dipeptidyl-Peptidase IV Inhibitors business.industry DPP-4 Inhibitors digestive oral and skin physiology Type 2 Diabetes Mellitus Cardiovascular risk DPP4- inhibitor Clinical Practice 030104 developmental biology Cardiovascular Diseases Glucagon-like peptide 1 receptor agonist business Cardiovascular outcomes

description

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and dipeptidyl peptidase-4 (DPP-4) inhibitors are so called “incretin-based therapies” (IBTs) that represent innovative therapeutic approaches and are commonly used in clinical practice for the treatment of type 2 diabetes mellitus (T2DM). The cardiovascular outcome trials (CVOTs) have provided useful information that has helped to shape changes in clinical practice guidelines for the management of T2DM. At the same time, the mechanisms that may explain the nonglycemic and cardiovascular (CV) benefits of these medications are still being explored. A summary of the main findings from CVOTs performed to-date with particular emphasis on various outcomes and inconsistencies observed in the trials is provided. Overall, available data is favourable to the early deployment of GLP-1RAs in clinical practice, fully in line with recommendations from international scientific guidelines, and based on their effects on glucose metabolism parameters, body weight reduction and CV outcomes. Evidence further suggest that the CV benefits of GLP-1RAs may not be a class effect, with GLP-1 analogues having a greater benefit rather than exendin-based agents.

year	journal	country	edition	language
2020-01-04	Metabolism

https://doi.org/10.1016/j.metabol.2020.154343